$53MRound, 22 September 2025
Funds the Phase 1/2 trial of EN-374 for X-CGD and expansion to oncology and sickle cell.
- Amount
- $53M
- Announced
- 22 September 2025
- Lead
- Gilead
- Other investors
- 5AM Ventures, Gates Foundation, Qatar Investment Authority, RTW
- Use of funds
- Funds the Phase 1/2 trial of EN-374 for X-CGD and expansion to oncology and sickle cell.
- Checked
- Announced by the company
- Sources
- Ensoma raises $53M (date approx) businesswire.com
Ensoma raises $53M (date approx) newsletter.parsers.vc